MEDIGUS TO PRESENT AT CANACCORD GENUITY MEDICAL TECHNOLOGY AND DIAGNOSTICS FORUM
OMER, Israel, November 9, 2015 — Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, announced today that Chris Rowland, CEO, and Gilad Mamlok, CFO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum on Thursday, November 19 at 11:40 a.m. ET. The conference will be held at the Westin Grand Central in New York City.
A live webcast of the presentation will be available to the public at http://wsw.com/webcast/canaccord20/mdgs. The webcast will be archived for 90 days following the live presentation. Medigus management will be available during the conference on November 19 for one-on-one meetings. To schedule a meeting, please contact your Canaccord Genuity representative or Miri Segal at email@example.com.
About Canaccord Genuity Group Inc.
Through its principal subsidiaries, Canaccord Genuity Group Inc. (the “Company”) is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional and corporate clients through comprehensive investment solutions, brokerage services and investment banking services. The Company has offices in 10 countries worldwide, including Wealth Management offices located in Canada, Australia, the UK, Guernsey, Jersey, and the Isle of Man. Canaccord Genuity, the international capital markets division, operates in Canada, the US, the UK, France, Ireland, Hong Kong, China, Singapore, Australia and Barbados. Canaccord Genuity Group Inc. is publicly traded under the symbol CF on the TSX and the symbol CF. on the London Stock Exchange.